Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite

Hillel Halkin*, Peter Mefn, Kenneth L. Melmon, Malcolm Rowland

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The blood concentrations of lidocaine and its active monodeethylated metabolite, monoethylglycinexylidide (MEGX), were measured in 31 patients who were receiving infusions of lidocaine intravenously. In 3 patients who were studied intensively, the elimination half-life of MEGX was 120 min, which was similar to the elimination half-life of lidocaine (139 min). An additional 3 patients demonstrated a higher ratio of the concentration in blood of MEGX to lidocaine, and the MEGX may have contributed, in 1 patient, to the central nervous system toxicity that occurred during the infusion. Elevated concentrations of MEGX in blood were associated with congestive heart failure (r = 0.5, p = 0.004). Our data suggest that the elimination of MEGX may be decreased in patients with depressed cardiac output and sympathomimetic compensation.

Original languageEnglish
Pages (from-to)669-676
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume17
Issue number6
DOIs
StatePublished - Jun 1975
Externally publishedYes

Fingerprint

Dive into the research topics of 'Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite'. Together they form a unique fingerprint.

Cite this